Stock Track | Lantheus Stock Plummets 31.47% on Q2 Earnings Miss and Lowered 2025 Guidance

Stock Track

Aug 06, 2025

Shares of Lantheus Holdings (LNTH) plummeted 31.47% in pre-market trading on Wednesday following the company's disappointing second-quarter results and reduced full-year guidance. The radiopharmaceutical-focused company faced headwinds from increased competition in the PSMA PET landscape, impacting its flagship product PYLARIFY.

Lantheus reported Q2 adjusted earnings of $1.57 per share, falling short of analysts' expectations of $1.67. Revenue for the quarter came in at $378 million, missing the consensus estimate of $389.1 million and representing a 4.1% year-over-year decline. The company's PYLARIFY sales, a key growth driver, decreased by 8.3% to $250.6 million due to heightened competition in the PSMA PET market.

In response to the challenging environment, Lantheus significantly lowered its full-year 2025 guidance. The company now expects revenue between $1.475 billion and $1.51 billion, down from the previous range of $1.55 billion to $1.59 billion. Adjusted earnings per share guidance was also reduced to $5.50-$5.70 from $6.60-$6.70. This substantial downward revision in outlook further contributed to the sharp decline in the stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1113581845"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113581845\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113581845?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 21:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113581845","market":"us","top_or_hot":-1,"title":"Stock Track | Lantheus Stock Plummets 31.47% on Q2 Earnings Miss and Lowered 2025 Guidance","media":"Stock Track","content":"<p>Shares of Lantheus Holdings (LNTH) plummeted 31.47% in pre-market trading on Wednesday following the company's disappointing second-quarter results and reduced full-year guidance. The radiopharmaceutical-focused company faced headwinds from increased competition in the PSMA PET landscape, impacting its flagship product PYLARIFY.</p>\n\n<p>Lantheus reported Q2 adjusted earnings of $1.57 per share, falling short of analysts' expectations of $1.67. Revenue for the quarter came in at $378 million, missing the consensus estimate of $389.1 million and representing a 4.1% year-over-year decline. The company's PYLARIFY sales, a key growth driver, decreased by 8.3% to $250.6 million due to heightened competition in the PSMA PET market.</p>\n\n<p>In response to the challenging environment, Lantheus significantly lowered its full-year 2025 guidance. The company now expects revenue between $1.475 billion and $1.51 billion, down from the previous range of $1.55 billion to $1.59 billion. Adjusted earnings per share guidance was also reduced to $5.50-$5.70 from $6.60-$6.70. This substantial downward revision in outlook further contributed to the sharp decline in the stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Lantheus Stock Plummets 31.47% on Q2 Earnings Miss and Lowered 2025 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Lantheus Stock Plummets 31.47% on Q2 Earnings Miss and Lowered 2025 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-06 21:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Lantheus Holdings (LNTH) plummeted 31.47% in pre-market trading on Wednesday following the company's disappointing second-quarter results and reduced full-year guidance. The radiopharmaceutical-focused company faced headwinds from increased competition in the PSMA PET landscape, impacting its flagship product PYLARIFY.</p>\n\n<p>Lantheus reported Q2 adjusted earnings of $1.57 per share, falling short of analysts' expectations of $1.67. Revenue for the quarter came in at $378 million, missing the consensus estimate of $389.1 million and representing a 4.1% year-over-year decline. The company's PYLARIFY sales, a key growth driver, decreased by 8.3% to $250.6 million due to heightened competition in the PSMA PET market.</p>\n\n<p>In response to the challenging environment, Lantheus significantly lowered its full-year 2025 guidance. The company now expects revenue between $1.475 billion and $1.51 billion, down from the previous range of $1.55 billion to $1.59 billion. Adjusted earnings per share guidance was also reduced to $5.50-$5.70 from $6.60-$6.70. This substantial downward revision in outlook further contributed to the sharp decline in the stock price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LNTH","symbol_name":"Lantheus Holdings, Inc.","start_time":0,"source_url":"","article_id":"1113581845","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113581845","pubTimestamp":1754488333,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Lantheus Holdings (LNTH) plummeted 31.47% in pre-market trading on Wednesday following the company's disappointing second-quarter results and reduced full-year guidance. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LNTH":"Lantheus Holdings, Inc."},"translate_title":"股票追踪|Lantheus股价暴跌31.47%，因Q2盈利未达预期并下调2025年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LNTH":1},"content_text":"Shares of Lantheus Holdings (LNTH) plummeted 31.47% in pre-market trading on Wednesday following the company's disappointing second-quarter results and reduced full-year guidance. The radiopharmaceutical-focused company faced headwinds from increased competition in the PSMA PET landscape, impacting its flagship product PYLARIFY.\nLantheus reported Q2 adjusted earnings of $1.57 per share, falling short of analysts' expectations of $1.67. Revenue for the quarter came in at $378 million, missing the consensus estimate of $389.1 million and representing a 4.1% year-over-year decline. The company's PYLARIFY sales, a key growth driver, decreased by 8.3% to $250.6 million due to heightened competition in the PSMA PET market.\nIn response to the challenging environment, Lantheus significantly lowered its full-year 2025 guidance. The company now expects revenue between $1.475 billion and $1.51 billion, down from the previous range of $1.55 billion to $1.59 billion. Adjusted earnings per share guidance was also reduced to $5.50-$5.70 from $6.60-$6.70. This substantial downward revision in outlook further contributed to the sharp decline in the stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}